JA2-WP5 EUnetHTA Joint Action 2 (2012-15)
2015 - PDF

The purpose of the assessment is to evaluate sorafenib Nexavar® and its use as a treatment of thyroid carcinoma

Final version of the assessment was published in March 2015

Below is the documentation provided by the Joint Assessment authoring team: